Trichostatin A reduced phospholipase C gamma-1 transcript and protein contents in MCF-7 breast cancer cells

• Published in: Biomedicine & pharmacotherapy 2012-02, Vol.66 (1), p.1-5
• Main Authors: Drzewiecka, H, Jagodzinski, P.P
• Format: Article
• Language: English
• Subjects: Breast Neoplasms - drug therapy; Breast Neoplasms - pathology; Cell Line, Tumor; Female; Half-Life; Histone deacetylase inhibitors; Histone Deacetylase Inhibitors - pharmacology; Humans; Hydroxamic Acids - pharmacology; Internal Medicine; MCF-7 breast cancer cells; Medical Education; Phospholipase C gamma - metabolism; PLCγ1; Protein Synthesis Inhibitors - pharmacology; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger - metabolism; TSA
• ISSN: 0753-3322; 1950-6007
• DOI: 10.1016/j.biopha.2011.09.005

Abstract It has recently been demonstrated that phospholipase C gamma-1 (PLCγ1) activation may contribute to breast carcinoma cell motility and their metastasis. Employing MCF-7 breast cancer cells, we showed the effect of trichostatin A (TSA) on the cellular contents of the PLCγ1 molecule. Using reverse transcription, real-time quantitative PCR and western blot analysis, we demonstrated that TSA reduced the PLCγ1 transcript and protein levels in MCF-7 cells. We also found that TSA decreased the half-life of the PLCγ1 transcript from approximately 7 hours to 5 hours. Moreover, we observed that protein synthesis appears to be essential in the TSA reduction of PLCγ1 mRNA stability. Since PLCγ1 activation is considered a key factor in the initiation of events that increase malignant cell motility, our observations may support the validity of TSA in anticancer studies.